Technical Analysis for MBIO - Mustang Bio, Inc.

Grade Last Price % Change Price Change
grade F 3.54 -11.94% -0.48
MBIO closed down 11.94 percent on Monday, June 24, 2019, on 47 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MBIO trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish -11.94%
Crossed Above 50 DMA Bullish -11.94%
180 Bullish Setup Bullish Swing Setup -11.94%
Expansion Pivot Buy Setup Bullish Swing Setup -11.94%

Older signals for MBIO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.
Medicine Biopharmaceutical Cancer Immunotherapy Immune System Cancer Treatments Gene Therapy Virotherapy Cancer Immunotherapy Kite Pharma Chimeric Antigen Receptor Cancer Immunotherapy Products Cellectis T Cell
Is MBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 10.2
52 Week Low 2.18
Average Volume 1,404,073
200-Day Moving Average 4.0847
50-Day Moving Average 3.8988
20-Day Moving Average 3.498
10-Day Moving Average 3.615
Average True Range 0.3468
ADX 13.33
+DI 21.9986
-DI 16.7178
Chandelier Exit (Long, 3 ATRs ) 3.0096
Chandelier Exit (Short, 3 ATRs ) 4.1606
Upper Bollinger Band 3.8766
Lower Bollinger Band 3.1194
Percent B (%b) 0.56
BandWidth 21.646655
MACD Line -0.0315
MACD Signal Line -0.0816
MACD Histogram 0.0501
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.32
Resistance 3 (R3) 4.40 4.23 4.19
Resistance 2 (R2) 4.23 4.03 4.18 4.15
Resistance 1 (R1) 3.88 3.91 3.79 3.80 4.10
Pivot Point 3.71 3.71 3.66 3.66 3.71
Support 1 (S1) 3.36 3.51 3.28 3.28 2.98
Support 2 (S2) 3.19 3.39 3.15 2.93
Support 3 (S3) 2.84 3.19 2.89
Support 4 (S4) 2.76